ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Non-Insulin Therapies for Diabetes Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-38T13322
Home | Market Reports | Health| Health Conditions| Endocrine Conditions
Global Non Insulin Therapies for Diabetes Market Research Report 2023
BUY CHAPTERS

Global Non-Insulin Therapies for Diabetes Market Research Report 2025

Code: QYRE-Auto-38T13322
Report
September 2025
Pages:91
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
GSK
Eli Lilly
Sumitomo Dainippon Pharma
Intarcia Therapeutics
Servier
Pfizer Inc
Merck
Dong-A Pharmaceutical
Luye Pharma Group
Eurofarma
Geropharm
Alkem Labs
SatRx
Jiangsu Hansoh Pharmaceutical
Novo Nordisk
Emisphere
Uni-Bio Science Group
Takeda
3SBio Inc
Jiangsu Hengrui Medicine

Non-Insulin Therapies for Diabetes Market Size

The global market for Non-Insulin Therapies for Diabetes was valued at US$ 38740 million in the year 2024 and is projected to reach a revised size of US$ 69790 million by 2031, growing at a CAGR of 8.9% during the forecast period.

Non-Insulin Therapies for Diabetes Market

Non-Insulin Therapies for Diabetes Market

There are several non-insulin therapies available for managing diabetes. These medications work in various ways to help regulate blood sugar levels.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Non-Insulin Therapies for Diabetes, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Insulin Therapies for Diabetes.
The Non-Insulin Therapies for Diabetes market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non-Insulin Therapies for Diabetes market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Insulin Therapies for Diabetes companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Non-Insulin Therapies for Diabetes Market Report

Report Metric Details
Report Name Non-Insulin Therapies for Diabetes Market
Accounted market size in year US$ 38740 million
Forecasted market size in 2031 US$ 69790 million
CAGR 8.9%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Alpha-glucosidase Inhibitors
  • Amylin Agonists
  • Biguanides
  • Dipeptidyl Peptidase-4 (DPP4) Inhibitors
  • Glinides / Meglitinides
  • GLP-1 Analogs / GLP-1 Agonists
  • Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
  • Sulfonylureas
  • Thiazolidinediones
  • Others
Segment by Application
  • Monitoring
  • Diagnosis
  • Treatment
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company GSK, Eli Lilly, Sumitomo Dainippon Pharma, Intarcia Therapeutics, Servier, Pfizer, Merck, Dong-A Pharmaceutical, Luye Pharma Group, Eurofarma, Geropharm, Alkem Labs, SatRx, Jiangsu Hansoh Pharmaceutical, Novo Nordisk, Emisphere, Uni-Bio Science Group, Takeda, 3SBio, Jiangsu Hengrui Medicine
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Non-Insulin Therapies for Diabetes company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Non-Insulin Therapies for Diabetes Market growing?

Ans: The Non-Insulin Therapies for Diabetes Market witnessing a CAGR of 8.9% during the forecast period 2025-2031.

What is the Non-Insulin Therapies for Diabetes Market size in 2031?

Ans: The Non-Insulin Therapies for Diabetes Market size in 2031 will be US$ 69790 million.

Who are the main players in the Non-Insulin Therapies for Diabetes Market report?

Ans: The main players in the Non-Insulin Therapies for Diabetes Market are GSK, Eli Lilly, Sumitomo Dainippon Pharma, Intarcia Therapeutics, Servier, Pfizer, Merck, Dong-A Pharmaceutical, Luye Pharma Group, Eurofarma, Geropharm, Alkem Labs, SatRx, Jiangsu Hansoh Pharmaceutical, Novo Nordisk, Emisphere, Uni-Bio Science Group, Takeda, 3SBio, Jiangsu Hengrui Medicine

What are the Application segmentation covered in the Non-Insulin Therapies for Diabetes Market report?

Ans: The Applications covered in the Non-Insulin Therapies for Diabetes Market report are Monitoring, Diagnosis, Treatment, Others

What are the Type segmentation covered in the Non-Insulin Therapies for Diabetes Market report?

Ans: The Types covered in the Non-Insulin Therapies for Diabetes Market report are Alpha-glucosidase Inhibitors, Amylin Agonists, Biguanides, Dipeptidyl Peptidase-4 (DPP4) Inhibitors, Glinides / Meglitinides, GLP-1 Analogs / GLP-1 Agonists, Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors, Sulfonylureas, Thiazolidinediones, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Alpha-glucosidase Inhibitors
1.2.3 Amylin Agonists
1.2.4 Biguanides
1.2.5 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
1.2.6 Glinides / Meglitinides
1.2.7 GLP-1 Analogs / GLP-1 Agonists
1.2.8 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
1.2.9 Sulfonylureas
1.2.10 Thiazolidinediones
1.3 Market by Application
1.3.1 Global Non-Insulin Therapies for Diabetes Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Monitoring
1.3.3 Diagnosis
1.3.4 Treatment
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Insulin Therapies for Diabetes Market Perspective (2020-2031)
2.2 Global Non-Insulin Therapies for Diabetes Growth Trends by Region
2.2.1 Global Non-Insulin Therapies for Diabetes Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Non-Insulin Therapies for Diabetes Historic Market Size by Region (2020-2025)
2.2.3 Non-Insulin Therapies for Diabetes Forecasted Market Size by Region (2026-2031)
2.3 Non-Insulin Therapies for Diabetes Market Dynamics
2.3.1 Non-Insulin Therapies for Diabetes Industry Trends
2.3.2 Non-Insulin Therapies for Diabetes Market Drivers
2.3.3 Non-Insulin Therapies for Diabetes Market Challenges
2.3.4 Non-Insulin Therapies for Diabetes Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Insulin Therapies for Diabetes Players by Revenue
3.1.1 Global Top Non-Insulin Therapies for Diabetes Players by Revenue (2020-2025)
3.1.2 Global Non-Insulin Therapies for Diabetes Revenue Market Share by Players (2020-2025)
3.2 Global Non-Insulin Therapies for Diabetes Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Non-Insulin Therapies for Diabetes Revenue
3.4 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio
3.4.1 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Insulin Therapies for Diabetes Revenue in 2024
3.5 Global Key Players of Non-Insulin Therapies for Diabetes Head office and Area Served
3.6 Global Key Players of Non-Insulin Therapies for Diabetes, Product and Application
3.7 Global Key Players of Non-Insulin Therapies for Diabetes, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Insulin Therapies for Diabetes Breakdown Data by Type
4.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Type (2020-2025)
4.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Type (2026-2031)
5 Non-Insulin Therapies for Diabetes Breakdown Data by Application
5.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Application (2020-2025)
5.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Non-Insulin Therapies for Diabetes Market Size (2020-2031)
6.2 North America Non-Insulin Therapies for Diabetes Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Non-Insulin Therapies for Diabetes Market Size by Country (2020-2025)
6.4 North America Non-Insulin Therapies for Diabetes Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-Insulin Therapies for Diabetes Market Size (2020-2031)
7.2 Europe Non-Insulin Therapies for Diabetes Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Non-Insulin Therapies for Diabetes Market Size by Country (2020-2025)
7.4 Europe Non-Insulin Therapies for Diabetes Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size (2020-2031)
8.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2020-2025)
8.4 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-Insulin Therapies for Diabetes Market Size (2020-2031)
9.2 Latin America Non-Insulin Therapies for Diabetes Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2020-2025)
9.4 Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size (2020-2031)
10.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2020-2025)
10.4 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Non-Insulin Therapies for Diabetes Introduction
11.1.4 GSK Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.1.5 GSK Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Introduction
11.2.4 Eli Lilly Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.2.5 Eli Lilly Recent Development
11.3 Sumitomo Dainippon Pharma
11.3.1 Sumitomo Dainippon Pharma Company Details
11.3.2 Sumitomo Dainippon Pharma Business Overview
11.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Introduction
11.3.4 Sumitomo Dainippon Pharma Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.3.5 Sumitomo Dainippon Pharma Recent Development
11.4 Intarcia Therapeutics
11.4.1 Intarcia Therapeutics Company Details
11.4.2 Intarcia Therapeutics Business Overview
11.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Introduction
11.4.4 Intarcia Therapeutics Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.4.5 Intarcia Therapeutics Recent Development
11.5 Servier
11.5.1 Servier Company Details
11.5.2 Servier Business Overview
11.5.3 Servier Non-Insulin Therapies for Diabetes Introduction
11.5.4 Servier Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.5.5 Servier Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Non-Insulin Therapies for Diabetes Introduction
11.6.4 Pfizer Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.6.5 Pfizer Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Non-Insulin Therapies for Diabetes Introduction
11.7.4 Merck Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.7.5 Merck Recent Development
11.8 Dong-A Pharmaceutical
11.8.1 Dong-A Pharmaceutical Company Details
11.8.2 Dong-A Pharmaceutical Business Overview
11.8.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Introduction
11.8.4 Dong-A Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.8.5 Dong-A Pharmaceutical Recent Development
11.9 Luye Pharma Group
11.9.1 Luye Pharma Group Company Details
11.9.2 Luye Pharma Group Business Overview
11.9.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Introduction
11.9.4 Luye Pharma Group Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.9.5 Luye Pharma Group Recent Development
11.10 Eurofarma
11.10.1 Eurofarma Company Details
11.10.2 Eurofarma Business Overview
11.10.3 Eurofarma Non-Insulin Therapies for Diabetes Introduction
11.10.4 Eurofarma Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.10.5 Eurofarma Recent Development
11.11 Geropharm
11.11.1 Geropharm Company Details
11.11.2 Geropharm Business Overview
11.11.3 Geropharm Non-Insulin Therapies for Diabetes Introduction
11.11.4 Geropharm Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.11.5 Geropharm Recent Development
11.12 Alkem Labs
11.12.1 Alkem Labs Company Details
11.12.2 Alkem Labs Business Overview
11.12.3 Alkem Labs Non-Insulin Therapies for Diabetes Introduction
11.12.4 Alkem Labs Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.12.5 Alkem Labs Recent Development
11.13 SatRx
11.13.1 SatRx Company Details
11.13.2 SatRx Business Overview
11.13.3 SatRx Non-Insulin Therapies for Diabetes Introduction
11.13.4 SatRx Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.13.5 SatRx Recent Development
11.14 Jiangsu Hansoh Pharmaceutical
11.14.1 Jiangsu Hansoh Pharmaceutical Company Details
11.14.2 Jiangsu Hansoh Pharmaceutical Business Overview
11.14.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Introduction
11.14.4 Jiangsu Hansoh Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.14.5 Jiangsu Hansoh Pharmaceutical Recent Development
11.15 Novo Nordisk
11.15.1 Novo Nordisk Company Details
11.15.2 Novo Nordisk Business Overview
11.15.3 Novo Nordisk Non-Insulin Therapies for Diabetes Introduction
11.15.4 Novo Nordisk Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.15.5 Novo Nordisk Recent Development
11.16 Emisphere
11.16.1 Emisphere Company Details
11.16.2 Emisphere Business Overview
11.16.3 Emisphere Non-Insulin Therapies for Diabetes Introduction
11.16.4 Emisphere Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.16.5 Emisphere Recent Development
11.17 Uni-Bio Science Group
11.17.1 Uni-Bio Science Group Company Details
11.17.2 Uni-Bio Science Group Business Overview
11.17.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Introduction
11.17.4 Uni-Bio Science Group Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.17.5 Uni-Bio Science Group Recent Development
11.18 Takeda
11.18.1 Takeda Company Details
11.18.2 Takeda Business Overview
11.18.3 Takeda Non-Insulin Therapies for Diabetes Introduction
11.18.4 Takeda Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.18.5 Takeda Recent Development
11.19 3SBio
11.19.1 3SBio Company Details
11.19.2 3SBio Business Overview
11.19.3 3SBio Non-Insulin Therapies for Diabetes Introduction
11.19.4 3SBio Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.19.5 3SBio Recent Development
11.20 Jiangsu Hengrui Medicine
11.20.1 Jiangsu Hengrui Medicine Company Details
11.20.2 Jiangsu Hengrui Medicine Business Overview
11.20.3 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Introduction
11.20.4 Jiangsu Hengrui Medicine Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025)
11.20.5 Jiangsu Hengrui Medicine Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
GSK
Eli Lilly
Sumitomo Dainippon Pharma
Intarcia Therapeutics
Servier
Pfizer Inc
Merck
Dong-A Pharmaceutical
Luye Pharma Group
Eurofarma
Geropharm
Alkem Labs
SatRx
Jiangsu Hansoh Pharmaceutical
Novo Nordisk
Emisphere
Uni-Bio Science Group
Takeda
3SBio Inc
Jiangsu Hengrui Medicine
List of Tables
 Table 1. Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Alpha-glucosidase Inhibitors
 Table 3. Key Players of Amylin Agonists
 Table 4. Key Players of Biguanides
 Table 5. Key Players of Dipeptidyl Peptidase-4 (DPP4) Inhibitors
 Table 6. Key Players of Glinides / Meglitinides
 Table 7. Key Players of GLP-1 Analogs / GLP-1 Agonists
 Table 8. Key Players of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
 Table 9. Global Non-Insulin Therapies for Diabetes Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 10. Global Non-Insulin Therapies for Diabetes Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 11. Global Non-Insulin Therapies for Diabetes Market Size by Region (2020-2025) & (US$ Million)
 Table 12. Global Non-Insulin Therapies for Diabetes Market Share by Region (2020-2025)
 Table 13. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 14. Global Non-Insulin Therapies for Diabetes Market Share by Region (2026-2031)
 Table 15. Non-Insulin Therapies for Diabetes Market Trends
 Table 16. Non-Insulin Therapies for Diabetes Market Drivers
 Table 17. Non-Insulin Therapies for Diabetes Market Challenges
 Table 18. Non-Insulin Therapies for Diabetes Market Restraints
 Table 19. Global Non-Insulin Therapies for Diabetes Revenue by Players (2020-2025) & (US$ Million)
 Table 20. Global Non-Insulin Therapies for Diabetes Market Share by Players (2020-2025)
 Table 21. Global Top Non-Insulin Therapies for Diabetes Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Insulin Therapies for Diabetes as of 2024)
 Table 22. Ranking of Global Top Non-Insulin Therapies for Diabetes Companies by Revenue (US$ Million) in 2024
 Table 23. Global 5 Largest Players Market Share by Non-Insulin Therapies for Diabetes Revenue (CR5 and HHI) & (2020-2025)
 Table 24. Global Key Players of Non-Insulin Therapies for Diabetes, Headquarters and Area Served
 Table 25. Global Key Players of Non-Insulin Therapies for Diabetes, Product and Application
 Table 26. Global Key Players of Non-Insulin Therapies for Diabetes, Date of Enter into This Industry
 Table 27. Mergers & Acquisitions, Expansion Plans
 Table 28. Global Non-Insulin Therapies for Diabetes Market Size by Type (2020-2025) & (US$ Million)
 Table 29. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2020-2025)
 Table 30. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 31. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2026-2031)
 Table 32. Global Non-Insulin Therapies for Diabetes Market Size by Application (2020-2025) & (US$ Million)
 Table 33. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Application (2020-2025)
 Table 34. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 35. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Application (2026-2031)
 Table 36. North America Non-Insulin Therapies for Diabetes Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. North America Non-Insulin Therapies for Diabetes Market Size by Country (2020-2025) & (US$ Million)
 Table 38. North America Non-Insulin Therapies for Diabetes Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Europe Non-Insulin Therapies for Diabetes Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Europe Non-Insulin Therapies for Diabetes Market Size by Country (2020-2025) & (US$ Million)
 Table 41. Europe Non-Insulin Therapies for Diabetes Market Size by Country (2026-2031) & (US$ Million)
 Table 42. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2020-2025) & (US$ Million)
 Table 44. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2026-2031) & (US$ Million)
 Table 45. Latin America Non-Insulin Therapies for Diabetes Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 49. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2020-2025) & (US$ Million)
 Table 50. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2026-2031) & (US$ Million)
 Table 51. GSK Company Details
 Table 52. GSK Business Overview
 Table 53. GSK Non-Insulin Therapies for Diabetes Product
 Table 54. GSK Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 55. GSK Recent Development
 Table 56. Eli Lilly Company Details
 Table 57. Eli Lilly Business Overview
 Table 58. Eli Lilly Non-Insulin Therapies for Diabetes Product
 Table 59. Eli Lilly Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 60. Eli Lilly Recent Development
 Table 61. Sumitomo Dainippon Pharma Company Details
 Table 62. Sumitomo Dainippon Pharma Business Overview
 Table 63. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product
 Table 64. Sumitomo Dainippon Pharma Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 65. Sumitomo Dainippon Pharma Recent Development
 Table 66. Intarcia Therapeutics Company Details
 Table 67. Intarcia Therapeutics Business Overview
 Table 68. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product
 Table 69. Intarcia Therapeutics Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 70. Intarcia Therapeutics Recent Development
 Table 71. Servier Company Details
 Table 72. Servier Business Overview
 Table 73. Servier Non-Insulin Therapies for Diabetes Product
 Table 74. Servier Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 75. Servier Recent Development
 Table 76. Pfizer Company Details
 Table 77. Pfizer Business Overview
 Table 78. Pfizer Non-Insulin Therapies for Diabetes Product
 Table 79. Pfizer Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 80. Pfizer Recent Development
 Table 81. Merck Company Details
 Table 82. Merck Business Overview
 Table 83. Merck Non-Insulin Therapies for Diabetes Product
 Table 84. Merck Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 85. Merck Recent Development
 Table 86. Dong-A Pharmaceutical Company Details
 Table 87. Dong-A Pharmaceutical Business Overview
 Table 88. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Product
 Table 89. Dong-A Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 90. Dong-A Pharmaceutical Recent Development
 Table 91. Luye Pharma Group Company Details
 Table 92. Luye Pharma Group Business Overview
 Table 93. Luye Pharma Group Non-Insulin Therapies for Diabetes Product
 Table 94. Luye Pharma Group Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 95. Luye Pharma Group Recent Development
 Table 96. Eurofarma Company Details
 Table 97. Eurofarma Business Overview
 Table 98. Eurofarma Non-Insulin Therapies for Diabetes Product
 Table 99. Eurofarma Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 100. Eurofarma Recent Development
 Table 101. Geropharm Company Details
 Table 102. Geropharm Business Overview
 Table 103. Geropharm Non-Insulin Therapies for Diabetes Product
 Table 104. Geropharm Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 105. Geropharm Recent Development
 Table 106. Alkem Labs Company Details
 Table 107. Alkem Labs Business Overview
 Table 108. Alkem Labs Non-Insulin Therapies for Diabetes Product
 Table 109. Alkem Labs Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 110. Alkem Labs Recent Development
 Table 111. SatRx Company Details
 Table 112. SatRx Business Overview
 Table 113. SatRx Non-Insulin Therapies for Diabetes Product
 Table 114. SatRx Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 115. SatRx Recent Development
 Table 116. Jiangsu Hansoh Pharmaceutical Company Details
 Table 117. Jiangsu Hansoh Pharmaceutical Business Overview
 Table 118. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product
 Table 119. Jiangsu Hansoh Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 120. Jiangsu Hansoh Pharmaceutical Recent Development
 Table 121. Novo Nordisk Company Details
 Table 122. Novo Nordisk Business Overview
 Table 123. Novo Nordisk Non-Insulin Therapies for Diabetes Product
 Table 124. Novo Nordisk Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 125. Novo Nordisk Recent Development
 Table 126. Emisphere Company Details
 Table 127. Emisphere Business Overview
 Table 128. Emisphere Non-Insulin Therapies for Diabetes Product
 Table 129. Emisphere Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 130. Emisphere Recent Development
 Table 131. Uni-Bio Science Group Company Details
 Table 132. Uni-Bio Science Group Business Overview
 Table 133. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product
 Table 134. Uni-Bio Science Group Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 135. Uni-Bio Science Group Recent Development
 Table 136. Takeda Company Details
 Table 137. Takeda Business Overview
 Table 138. Takeda Non-Insulin Therapies for Diabetes Product
 Table 139. Takeda Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 140. Takeda Recent Development
 Table 141. 3SBio Company Details
 Table 142. 3SBio Business Overview
 Table 143. 3SBio Non-Insulin Therapies for Diabetes Product
 Table 144. 3SBio Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 145. 3SBio Recent Development
 Table 146. Jiangsu Hengrui Medicine Company Details
 Table 147. Jiangsu Hengrui Medicine Business Overview
 Table 148. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product
 Table 149. Jiangsu Hengrui Medicine Revenue in Non-Insulin Therapies for Diabetes Business (2020-2025) & (US$ Million)
 Table 150. Jiangsu Hengrui Medicine Recent Development
 Table 151. Research Programs/Design for This Report
 Table 152. Key Data Information from Secondary Sources
 Table 153. Key Data Information from Primary Sources
 Table 154. Authors List of This Report


List of Figures
 Figure 1. Non-Insulin Therapies for Diabetes Picture
 Figure 2. Global Non-Insulin Therapies for Diabetes Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Non-Insulin Therapies for Diabetes Market Share by Type: 2024 VS 2031
 Figure 4. Alpha-glucosidase Inhibitors Features
 Figure 5. Amylin Agonists Features
 Figure 6. Biguanides Features
 Figure 7. Dipeptidyl Peptidase-4 (DPP4) Inhibitors Features
 Figure 8. Glinides / Meglitinides Features
 Figure 9. GLP-1 Analogs / GLP-1 Agonists Features
 Figure 10. Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Features
 Figure 11. Sulfonylureas Features
 Figure 12. Thiazolidinediones Features
 Figure 13. Global Non-Insulin Therapies for Diabetes Market Size by Application (2020-2031) & (US$ Million)
 Figure 14. Global Non-Insulin Therapies for Diabetes Market Share by Application: 2024 VS 2031
 Figure 15. Monitoring Case Studies
 Figure 16. Diagnosis Case Studies
 Figure 17. Treatment Case Studies
 Figure 18. Others Case Studies
 Figure 19. Non-Insulin Therapies for Diabetes Report Years Considered
 Figure 20. Global Non-Insulin Therapies for Diabetes Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 21. Global Non-Insulin Therapies for Diabetes Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 22. Global Non-Insulin Therapies for Diabetes Market Share by Region: 2024 VS 2031
 Figure 23. Global Non-Insulin Therapies for Diabetes Market Share by Players in 2024
 Figure 24. Global Top Non-Insulin Therapies for Diabetes Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Insulin Therapies for Diabetes as of 2024)
 Figure 25. The Top 10 and 5 Players Market Share by Non-Insulin Therapies for Diabetes Revenue in 2024
 Figure 26. North America Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. North America Non-Insulin Therapies for Diabetes Market Share by Country (2020-2031)
 Figure 28. United States Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Canada Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Europe Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Europe Non-Insulin Therapies for Diabetes Market Share by Country (2020-2031)
 Figure 32. Germany Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. France Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. U.K. Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Italy Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Russia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Nordic Countries Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Asia-Pacific Non-Insulin Therapies for Diabetes Market Share by Region (2020-2031)
 Figure 40. China Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Japan Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. South Korea Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Southeast Asia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. India Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Australia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Latin America Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Latin America Non-Insulin Therapies for Diabetes Market Share by Country (2020-2031)
 Figure 48. Mexico Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Brazil Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 51. Middle East & Africa Non-Insulin Therapies for Diabetes Market Share by Country (2020-2031)
 Figure 52. Turkey Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 53. Saudi Arabia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 54. UAE Non-Insulin Therapies for Diabetes Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 55. GSK Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 56. Eli Lilly Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 57. Sumitomo Dainippon Pharma Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 58. Intarcia Therapeutics Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 59. Servier Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 60. Pfizer Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 61. Merck Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 62. Dong-A Pharmaceutical Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 63. Luye Pharma Group Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 64. Eurofarma Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 65. Geropharm Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 66. Alkem Labs Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 67. SatRx Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 68. Jiangsu Hansoh Pharmaceutical Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 69. Novo Nordisk Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 70. Emisphere Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 71. Uni-Bio Science Group Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 72. Takeda Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 73. 3SBio Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 74. Jiangsu Hengrui Medicine Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2020-2025)
 Figure 75. Bottom-up and Top-down Approaches for This Report
 Figure 76. Data Triangulation
 Figure 77. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global Non Insulin Hypoglycemic Drug Market Research Report 2025
Diabetes Medicines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Diabetes Therapy Device Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Antidiabetic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Non Small Cell Lung Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Type 2 Diabetes Therapeutics Market Research Report 2025
Diabetic Retinopathy Fundus Image assisted Diagnosis Software Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Non opioid Topical Pain Relief Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Diabetic Therapeutic Drugs Market Research Report 2025
Over the Counter Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Prescription Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Chronic Metabolic Disease Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Combination Anti Diabetes Drugs Market Research Report 2025
Influenza Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Still s Disease Treatment Market Research Report 2025
Super Generic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Glycemic Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Biopharma Cosmetics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Digital Health and Digital Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Drug Delivery Technologies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions